Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma.
Labrinidis A, Diamond P, Martin S, Hay S, Liapis V, Zinonos I, Sims NA, Atkins GJ, Vincent C, Ponomarev V, Findlay DM, Zannettino AC, Evdokiou A. Labrinidis A, et al. Among authors: zinonos i. Clin Cancer Res. 2009 Mar 15;15(6):1998-2009. doi: 10.1158/1078-0432.CCR-08-2444. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276263 Free PMC article.
Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer.
Zinonos I, Luo KW, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ko CH, Yue GG, Lau CB, Ingman W, Ponomarev V, Atkins GJ, Findlay DM, Zannettino AC, Evdokiou A. Zinonos I, et al. Int J Oncol. 2014 Aug;45(2):532-40. doi: 10.3892/ijo.2014.2468. Epub 2014 May 27. Int J Oncol. 2014. PMID: 24865346 Free PMC article.
Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.
Liapis V, Labrinidis A, Zinonos I, Hay S, Ponomarev V, Panagopoulos V, DeNichilo M, Ingman W, Atkins GJ, Findlay DM, Zannettino ACW, Evdokiou A. Liapis V, et al. Among authors: zinonos i. Cancer Lett. 2015 Feb 1;357(1):160-169. doi: 10.1016/j.canlet.2014.11.020. Epub 2014 Nov 15. Cancer Lett. 2015. PMID: 25444931 Free PMC article.
Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A, DeNichilo MO, Panagopoulos V, Zinonos I, Liapis V, Hay S, Ingman W, Ponomarev V, Atkins G, Findlay D, Zannettino A, Evdokiou A. Zysk A, et al. Among authors: zinonos i. Cancer Lett. 2017 Feb 1;386:141-150. doi: 10.1016/j.canlet.2016.11.013. Epub 2016 Nov 16. Cancer Lett. 2017. PMID: 27865798 Free PMC article.
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
Liapis V, Zysk A, DeNichilo M, Zinonos I, Hay S, Panagopoulos V, Shoubridge A, Difelice C, Ponomarev V, Ingman W, Atkins GJ, Findlay DM, Zannettino ACW, Evdokiou A. Liapis V, et al. Among authors: zinonos i. Cancer Med. 2017 Sep;6(9):2164-2176. doi: 10.1002/cam4.1115. Epub 2017 Aug 10. Cancer Med. 2017. PMID: 28799237 Free PMC article.
Nutlin-3a is a potential therapeutic for ewing sarcoma.
Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF, Neilsen PM. Pishas KI, et al. Among authors: zinonos i. Clin Cancer Res. 2011 Feb 1;17(3):494-504. doi: 10.1158/1078-0432.CCR-10-1587. Epub 2010 Nov 23. Clin Cancer Res. 2011. PMID: 21098696
19 results